Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients.

Young Kul Jung, Jong Eun Yeon, Kwang Gyun Lee, Eun Seok Jung, Jeong Han Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Soon-Ho Um, Ho Sang Ryu, Kwan Soo Byun

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared to that of ADV maintenance. The indication for ADV treatment cessation was an undetectable level of hepatitis B virus (HBV) DNA documented on two occasions at least 6 months apart. All patients received additional ADV for at least 12 months after the confirmation of undetectable HBV DNA (Cobas TaqMan PCR assay, <70 copies/mL). Of 36 patients who had a sufficient ADV therapeutic effect, 19 discontinued ADV treatment, while the others maintained it. A virologic rebound was arbitrarily defined as the redetection of HBV DNA at a level higher than 10(5) copies/mL. In the ADV discontinuation group, ADV treatment and additional therapy were administered for medians of 33 months (range, 12-47 months) and 18 months, respectively. The patients were followed for a median of 12 months (range, 3-30 months) after ADV cessation. During that period, 18 of 19 patients (95%) experienced viral relapse. Viral rebound was observed in six patients (32%). However, 12 of 18 patients (67%) exhibited serum HBV DNA levels of less than (5) copies/mL. Biochemical relapses were observed in four of the six patients with viral rebound. In the ADV maintenance group, patients were treated for a median of 53 months (range, 31-85 months), and 9 patients (53%) experienced viral breakthrough. During short-term follow-up after ADV discontinuation, most patients (95%) exhibited viral relapse, whereas and viral breakthrough occurred in about half of patients (53%) maintained on ADV therapy. Therefore, the durability of virologic response after ADV discontinuation in LMV-R patients was unsatisfactory. In addition, and viral breakthrough was not infrequent in the ADV continuation group.

Original languageEnglish
Pages (from-to)261-267
Number of pages7
JournalThe Korean journal of hepatology
Volume17
Issue number4
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

Lamivudine
Chronic Hepatitis B
Hepatitis B virus
DNA
adefovir
Recurrence
Maintenance
Withholding Treatment
Therapeutic Uses
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{8c3e50ea29524225b548021901b4c1ef,
title = "Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients.",
abstract = "We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared to that of ADV maintenance. The indication for ADV treatment cessation was an undetectable level of hepatitis B virus (HBV) DNA documented on two occasions at least 6 months apart. All patients received additional ADV for at least 12 months after the confirmation of undetectable HBV DNA (Cobas TaqMan PCR assay, <70 copies/mL). Of 36 patients who had a sufficient ADV therapeutic effect, 19 discontinued ADV treatment, while the others maintained it. A virologic rebound was arbitrarily defined as the redetection of HBV DNA at a level higher than 10(5) copies/mL. In the ADV discontinuation group, ADV treatment and additional therapy were administered for medians of 33 months (range, 12-47 months) and 18 months, respectively. The patients were followed for a median of 12 months (range, 3-30 months) after ADV cessation. During that period, 18 of 19 patients (95{\%}) experienced viral relapse. Viral rebound was observed in six patients (32{\%}). However, 12 of 18 patients (67{\%}) exhibited serum HBV DNA levels of less than (5) copies/mL. Biochemical relapses were observed in four of the six patients with viral rebound. In the ADV maintenance group, patients were treated for a median of 53 months (range, 31-85 months), and 9 patients (53{\%}) experienced viral breakthrough. During short-term follow-up after ADV discontinuation, most patients (95{\%}) exhibited viral relapse, whereas and viral breakthrough occurred in about half of patients (53{\%}) maintained on ADV therapy. Therefore, the durability of virologic response after ADV discontinuation in LMV-R patients was unsatisfactory. In addition, and viral breakthrough was not infrequent in the ADV continuation group.",
author = "Jung, {Young Kul} and Yeon, {Jong Eun} and Lee, {Kwang Gyun} and Jung, {Eun Seok} and Kim, {Jeong Han} and Kim, {Ji Hoon} and Seo, {Yeon Seok} and Yim, {Hyung Joon} and Soon-Ho Um and Ryu, {Ho Sang} and Byun, {Kwan Soo}",
year = "2011",
month = "12",
day = "1",
doi = "10.3350/kjhep.2011.17.4.261",
language = "English",
volume = "17",
pages = "261--267",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "4",

}

TY - JOUR

T1 - Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients.

AU - Jung, Young Kul

AU - Yeon, Jong Eun

AU - Lee, Kwang Gyun

AU - Jung, Eun Seok

AU - Kim, Jeong Han

AU - Kim, Ji Hoon

AU - Seo, Yeon Seok

AU - Yim, Hyung Joon

AU - Um, Soon-Ho

AU - Ryu, Ho Sang

AU - Byun, Kwan Soo

PY - 2011/12/1

Y1 - 2011/12/1

N2 - We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared to that of ADV maintenance. The indication for ADV treatment cessation was an undetectable level of hepatitis B virus (HBV) DNA documented on two occasions at least 6 months apart. All patients received additional ADV for at least 12 months after the confirmation of undetectable HBV DNA (Cobas TaqMan PCR assay, <70 copies/mL). Of 36 patients who had a sufficient ADV therapeutic effect, 19 discontinued ADV treatment, while the others maintained it. A virologic rebound was arbitrarily defined as the redetection of HBV DNA at a level higher than 10(5) copies/mL. In the ADV discontinuation group, ADV treatment and additional therapy were administered for medians of 33 months (range, 12-47 months) and 18 months, respectively. The patients were followed for a median of 12 months (range, 3-30 months) after ADV cessation. During that period, 18 of 19 patients (95%) experienced viral relapse. Viral rebound was observed in six patients (32%). However, 12 of 18 patients (67%) exhibited serum HBV DNA levels of less than (5) copies/mL. Biochemical relapses were observed in four of the six patients with viral rebound. In the ADV maintenance group, patients were treated for a median of 53 months (range, 31-85 months), and 9 patients (53%) experienced viral breakthrough. During short-term follow-up after ADV discontinuation, most patients (95%) exhibited viral relapse, whereas and viral breakthrough occurred in about half of patients (53%) maintained on ADV therapy. Therefore, the durability of virologic response after ADV discontinuation in LMV-R patients was unsatisfactory. In addition, and viral breakthrough was not infrequent in the ADV continuation group.

AB - We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared to that of ADV maintenance. The indication for ADV treatment cessation was an undetectable level of hepatitis B virus (HBV) DNA documented on two occasions at least 6 months apart. All patients received additional ADV for at least 12 months after the confirmation of undetectable HBV DNA (Cobas TaqMan PCR assay, <70 copies/mL). Of 36 patients who had a sufficient ADV therapeutic effect, 19 discontinued ADV treatment, while the others maintained it. A virologic rebound was arbitrarily defined as the redetection of HBV DNA at a level higher than 10(5) copies/mL. In the ADV discontinuation group, ADV treatment and additional therapy were administered for medians of 33 months (range, 12-47 months) and 18 months, respectively. The patients were followed for a median of 12 months (range, 3-30 months) after ADV cessation. During that period, 18 of 19 patients (95%) experienced viral relapse. Viral rebound was observed in six patients (32%). However, 12 of 18 patients (67%) exhibited serum HBV DNA levels of less than (5) copies/mL. Biochemical relapses were observed in four of the six patients with viral rebound. In the ADV maintenance group, patients were treated for a median of 53 months (range, 31-85 months), and 9 patients (53%) experienced viral breakthrough. During short-term follow-up after ADV discontinuation, most patients (95%) exhibited viral relapse, whereas and viral breakthrough occurred in about half of patients (53%) maintained on ADV therapy. Therefore, the durability of virologic response after ADV discontinuation in LMV-R patients was unsatisfactory. In addition, and viral breakthrough was not infrequent in the ADV continuation group.

UR - http://www.scopus.com/inward/record.url?scp=84861304867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861304867&partnerID=8YFLogxK

U2 - 10.3350/kjhep.2011.17.4.261

DO - 10.3350/kjhep.2011.17.4.261

M3 - Article

VL - 17

SP - 261

EP - 267

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 4

ER -